Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(4):545–550. doi: 10.1038/bjc.1997.423

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).

R Chacon, L Romero Acuña, C Blajman, C Galvez, M Bruno, A Romero, G Chiessa, M Bader, R Schwan, C Albera, M T Santarelli, F Sousa Martínez, J Nadal, M Viniegra
PMCID: PMC2227983  PMID: 9275035

Abstract

A randomized trial to compare adjuvant treatment with an alternating regimen with conventional chemotherapy was performed. A total of 589 node-positive patients were included and stratified according to number of positive nodes (N1-3 and N > 4) and menopausal status. Premenopausal N1-3 patients were randomized to cyclophosphamide, methotrexate and fluorouracil (CMF) or CMF/4'-epirubicin, cyclophosphamide (EC), post-menopausal N1-3 patients to fluorouracil, 4 epirubicin, cyclophosphamide (FEC) or CMF/EC and pre- and post-menopausal patients with N > or = 4 to fluorouracil, 4' epirubicin, cyclophosphamide, methotrexate, prednisone (FECMP) or CMF/EC. In premenopausal patients, CMF was superior to CMF/EC in terms of disease-free survival (DFS) (65% vs 45%, P = 0.0149) and survival (72.3% vs 50.2%, P = 0.0220) whereas, for N > or = 4 patients, differences between FECMP and CMF/EC did not achieve statistical significance (DFS 35% vs 26.2%; survival 50% vs 38.1%, P = NS). For post-menopausal patients, FEC was superior to CMF/EC in DFS (58.6% vs 36.8%, P = 0.0215) and survival (66.2% vs 46%, P = 0.0155). In post-menopausal patients with N > 4, differences favouring CMF/EC were significant in DFS (40.4% vs 22%, P = 0.0371) but not in survival (47.4% vs 32.2%, P = 0.1185). Alternating regimens did not offer better results in premenopausal and post-menopausal N1-3 patients. Results regarding post-menopausal N > 4 women require further confirmation.

Full text

PDF
545

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739–746. doi: 10.7326/0003-4819-104-6-739. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA. 1995 Feb 15;273(7):542–547. [PubMed] [Google Scholar]
  3. Buzdar A. U., Hortobagyi G. N., Smith T. L., Kau S., Marcus C., Holmes F. A., Hug V., Fraschini G., Ames F. C., Martin R. G. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988 Nov 15;62(10):2098–2104. doi: 10.1002/1097-0142(19881115)62:10<2098::aid-cncr2820621005>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. Evans W. K., Feld R., Murray N., Willan A., Coy P., Osoba D., Shepherd F. A., Clark D. A., Levitt M., MacDonald A. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987 Oct;107(4):451–458. doi: 10.7326/0003-4819-107-4-451. [DOI] [PubMed] [Google Scholar]
  5. Falkson G., Tormey D. C., Carey P., Witte R., Falkson H. C. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer. 1991;27(8):973–977. doi: 10.1016/0277-5379(91)90261-b. [DOI] [PubMed] [Google Scholar]
  6. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  7. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Spittle M. F., Hill B. T., Ostrowski M. J., Macrae K. D., Bates T. D., Martin W. M., Nicol N. T., Edelstyn G. A. A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer. Eur J Cancer Clin Oncol. 1987 Aug;23(8):1155–1162. doi: 10.1016/0277-5379(87)90149-0. [DOI] [PubMed] [Google Scholar]
  9. Tormey D. C., Gray R., Abeloff M. D., Roseman D. L., Gilchrist K. W., Barylak E. J., Stott P., Falkson G. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992 Dec;10(12):1848–1856. doi: 10.1200/JCO.1992.10.12.1848. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES